Palivizumab (Synagis®) prophylaxis for respiratory syncytial virus infection in preterm infants
Record ID 32012000569
English
Authors' recommendations:
Palivizumab (PLV) (Synagis®; MedImmune Inc.) is an antibody used as a prophylaxis for respiratory syncytial virus (RSV) infection, a common infection that can be serious in young babies, particularly in premature infants.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
The report may be purchased from:http://www.hayesinc.com/hayes/crd/?crd=13841
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Infant, Premature
- Antibodies, Monoclonal, Humanized
- Antiviral Agents
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2012 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.